# Safety Study of Two Repeat Doses of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults

> **NCT01124565** · PHASE2 · COMPLETED · sponsor: **Revance Therapeutics, Inc.** · enrollment: 40 (actual)

## Conditions studied

- Lateral Canthal Lines
- Crow's Feet
- Facial Wrinkles

## Interventions

- **DRUG:** RT001

## Key facts

- **NCT ID:** NCT01124565
- **Lead sponsor:** Revance Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2010-07
- **Final completion:** 2010-07
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2014-01-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01124565

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01124565, "Safety Study of Two Repeat Doses of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01124565. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*